Abstract

In this issue of Value in Health, the ISPOR Task Force on Use of Pharmacoeconomic/Health Economic Information in Health Care Decision Making presents a report with information intended to ensure that pharmacoeconomic/health economic (PE/HE) research is attuned to the needs of decision makers and to provide tools they can use to interpret and apply these studies [1]. After reviewing the literature on decision makers’ attitudes toward PE/ HE evaluations, the task force has identified a number of key decision-maker concerns that may limit their use of results from PE/HE studies. In addition, following a review of published guidelines and discussions with managed care pharmacy opinion leaders, the task force suggests some additional reporting requirements to address these concerns.